Form 4: Cyclacel Pharmaceuticals Director David Natan Granted 700,000 Stock Options

Director David Natan receives 700,000 non-qualified stock options in Cyclacel Pharmaceuticals, exercisable immediately, replacing previously reported shares.

Summary

• David Natan, a director of Cyclacel Pharmaceuticals, was granted 700,000 non-qualified stock options on February 26, 2025.
• These options allow Natan to purchase shares of Cyclacel Pharmaceuticals' common stock at an exercise price of $0.33.
• The options were granted in consideration for his services as a director.
• The options became exercisable immediately on the grant date.
• The grant replaces shares of common stock previously reported in Table I of the Reporting Person's Form 4 filed on January 7, 2025.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants to a director, which is generally neutral. The grant itself can be seen as a positive sign of aligning interests, but it's not a major event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The immediate exercisability of the options provides the director with immediate potential benefit.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard practice for compensating directors of publicly traded companies, aligning their interests with shareholders through equity ownership.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the pharmaceutical industry to incentivize performance and align interests with shareholders.
• The size of the grant (700,000 options) would need to be compared to grants at comparable companies to determine if it is above or below industry standards.
• Companies like Amgen, Gilead Sciences, and Biogen often use stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a way to incentivize the director to act in their best interests.

Key Dates